Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy

Trends in cancer, Год журнала: 2019, Номер 5(5), С. 308 - 324

Опубликована: Апрель 30, 2019

Язык: Английский

---

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Cell, Год журнала: 2024, Номер 187(7), С. 1617 - 1635

Опубликована: Март 1, 2024

Язык: Английский

---

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges

Science Advances, Год журнала: 2022, Номер 8(4)

Опубликована: Янв. 26, 2022

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications in cancer management. While its role guiding precision medicine certain tumors via noninvasive detection of susceptibility and resistance alterations is now well established, recent evidence pointed to more generalizable use treatment monitoring. Quantitative changes ctDNA levels over time (i.e., kinetics) have shown potential an early indicator therapeutic efficacy could enable adaptation. However, kinetics are complex heterogeneous, affected by biology, host physiology, factors. This review outlines the current preclinical clinical knowledge how on-treatment be applied research collect support implementation daily practice.

Язык: Английский

---

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Frontiers in Oncology, Год журнала: 2021, Номер 11

Опубликована: Ноя. 18, 2021

Circulating tumor DNA (ctDNA) is cell-free (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating cells. Recently, ctDNA has emerged as a promising non-invasive biomarker clinical oncology. Analysis of opens up new avenues for individualized cancer diagnosis and therapy various types tumors. Evidence suggests minimum residual disease (MRD) closely associated with recurrence, thus identifying specific genetic molecular alterations novel MRD detection targets using been research focus. considered prognostic marker to identify individuals at increased risk recurrence who may benefit treatment. This review summarizes current knowledge solid tumors, focusing on potential applications challenges. We describe state methods milestones development discuss how analysis be an alternative tissue biopsy. Additionally, we evaluate utility such assessment, monitoring response, resistance mechanism analysis. aids assessing treatment patient prognosis, recurrence. Moreover, this highlights advancements utilizing monitor lung cancer, breast colon cancer. Overall, application ctDNA-based can assist decision-making improve outcomes

Язык: Английский

---

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities

Cell Reports, Год журнала: 2022, Номер 38(9), С. 110448 - 110448

Опубликована: Март 1, 2022

Язык: Английский

---